Promogen-MAB, LLC
Pharmaceuticals - , ,
Promogen-MAB, LLC Employees
Promogen-MAB, LLC Senior Management
Promogen-MAB, LLC Details
Promogen-MAB, LLC, is one of the first Russian companies actively engaged in the development of antibody biosimilars. Its main focus is the biosimilar of the monoclonal antibody ranked within the top 10 best selling drugs. Substantial effort has been dedicated to the development of the highly efficient cell line and technology to ensure the high-yield production of the biosimilar antibody. Preclinical studies have been successfully completed confirming biosimilarity and safety in a variety of in-vitro and in-vivo tests. Phase I of the clinical trials will be initiated in Russia in the near future. We have invested resources and efforts to provide the high quality product with a belief it has a high potential to provide not only considerable revenue but also to make the very expensive but at the same time very essential drug more affordable to the patients and improve their quality of life. With the cell line developed in Europe, MCB prepared and characterized in the US and preclinical studies done in accordance with the EMA requirements we believe our product is of interest not only in Russia but in the other parts of the world. Lead investor is Bioprocess Capital Ventures Fund. Management Company of the Russian venture fund Bioprocess Capital Ventures focused on biotechnology and fine chemistry start-ups from Russia and other countries and is very much looking forward to meeting new partners.
